Neurocrine Biosciences
NBIX
221 hedge funds and large institutions have $4.36B invested in Neurocrine Biosciences in 2017 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 85 increasing their positions, 72 reducing their positions, and 37 closing their positions.
18% more capital invested
Capital invested by funds: $3.68B → $4.36B (+$678M)
18% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 72
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
16% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 37
10.06% more ownership
Funds ownership: 97.64% → 107.69% (+10%)
1% more funds holding
Funds holding: 218 → 221 (+3)
22% less call options, than puts
Call options by funds: $16.7M | Put options by funds: $21.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$260M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$148M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$84.2M |
| 4 |
HM
HealthCor Management
New York
|
+$64.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$57.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$46.7M |
| 2 |
SIG
Senator Investment Group
New York
|
-$39M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$29.9M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$29.7M |
| 5 |
Jennison Associates
New York
|
-$15.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
251
Quantbot Technologies
New York
| – | -$68K | -1,581 | Closed |
|
|
SEC
252
Seven Eight Capital
New York
| – | -$13K | -300 | Closed |
|
|
CLOS
253
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$11K | -260 | Closed |
|
|
ASN
254
Advisory Services Network
Atlanta,
Georgia
| – | -$4K | -100 | Closed |
|
|
FMA
255
FNY Managed Accounts
New York
| – | -$3K | -82 | Closed |
|
256
Walleye Trading
New York
| – | -$3 | -75 | Closed |
|
|
EFSCE
257
Enterprise Financial Services Corp (EFSC)
Clayton,
Missouri
| – | -$1K | -23 | Closed |
|
|
MPWT
258
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | -$433 | -10 | Closed |
|
NBIX Hedge Fund Activity: Q2 2017 in Review
221 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2017, worth a combined $4.36B — up 18% from $3.68B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new NBIX positions and 37 closed out — a net gain of 6 holders — while 85 added to existing stakes and 72 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $260M. The largest seller was Citadel Advisors, cutting an estimated $46.7M.
- 221 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2017, up from 218 in Q1 2017.
- Funds reported $4.36B of Neurocrine Biosciences stock for Q2 2017, up 18% quarter-over-quarter.
- 43 funds opened new Neurocrine Biosciences positions in Q2 2017 and 37 closed out, a net change of +6 holders.
- The largest Neurocrine Biosciences buyer in Q2 2017 was Janus Henderson Group, an estimated $260M added.
- The largest Neurocrine Biosciences seller in Q2 2017 was Citadel Advisors, an estimated $46.7M sold.
Based on aggregated 13F filings for Q2 2017.